Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4527 |
Seclidemstat
SP-2577 |
Histone Demethylase | Chromatin/Epigenetic |
Seclidemstat (SP-2577) 是非竞争性可逆KDM1A (LSD1)抑制剂,可用于尤文肉瘤的研究。它促进 SWI/SNF 复合物突变卵巢癌的抗肿瘤免疫,并抑制病毒产生、病毒 DNA 复制和晚期基因表达。 | |||
T13166 |
TK216
|
Others; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Others |
TK216 是一种口服有效的 E26 转录因子抑制剂,具有抗癌活性。它直接结合 EWS-FLI1 并抑制 EWS-FLI1 蛋白质相互作用,也可阻止 EWS-FLI1 与 RNA 解旋酶 A 的结合。 | |||
T2465 |
PF-562271
PF562271,PF 562271 |
FAK; PYK2; CDK | Angiogenesis; Cell Cycle/Checkpoint; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PF-562271 是一种可逆的,有效的,ATP 竞争性的 FAK (IC50:1.5 nM)和 Pyk2 (IC50:13 nM)激酶抑制剂。 | |||
T21768 |
PF-562271 hydrochloride
PF-562271 HCl |
FAK; PYK2; CDK | Angiogenesis; Cell Cycle/Checkpoint; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PF-562271 hydrochloride (PF-562271 HCl) 是一种可逆的,有效的,ATP 竞争性的 FAK (IC50:1.5 nM)和 Pyk2 (IC50:13 nM)激酶抑制剂。 | |||
T83064 | Anti-hepatic fibrosis agent 2 | ||
Fibrosis agent 2为针对Ewing肉瘤断点区域1 (EWSR1) 的特定抗纤维化化合物。 | |||
T76759 | Robatumumab | ||
Robatumumab (Sch 717454) 为针对人胰岛素样生长因子 1 受体(anti-humanIGF-1R)的抗体,展现出抗肿瘤及阻止癌细胞增殖的作用,适用于骨肉瘤与尤文肉瘤的研究。 | |||
T78982 |
BK60106
|
Apoptosis | Apoptosis |
BK60106是一种选择性针对CD99的抑制剂,能够直接与CD99的胞外结构域结合。它能特异性地诱导尤文肉瘤(ES)细胞凋亡(apoptosis),而且伴随的DNA损伤相对较少。 | |||
T39439 |
Seclidemstat mesylate
SP-2577 mesylate |
||
Seclidemstat mesylate (SP-2577) is a highly effective and reversible inhibitor of KDM1A (LSD1), with a Ki of 31 nM and an IC 50 of 13 nM. It demonstrates significant potential in promoting antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, while also exhibiting inhibitory effects on virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate is a valuable tool for studying Ewing Sarcoma in research settings. | |||
T36253 | dTAGV-1 | ||
Degrader targeting mutant FKBP12F36V fusion proteins. Comprises a ligand selective for F36V single-point mutated FKBP12, a linker and a von Hippel-Lindau (VHL)-binding ligand. Induces potent and selective degradation of FKBP12F36V fusion proteins in vitro and in vivo. Selectively degrades FKBP12F36V-EWS/FLI fusion proteins and inhibits cell proliferation in FKBP12F36V-EWS/FLI-expressing Ewing sarcoma cells. Hydrochloride salt (Cat.No. 7374) available; suitable for in vivo use. Negative control... |